In vivo pretargeting stands as a promising approach to harnessing the exquisite tumor-targeting properties of antibodies for nuclear imaging and therapy while simultaneously skirting their ...
Journal of Nuclear Medicine April 2026, jnumed.126.272204; DOI: https://doi.org/10.2967/jnumed.126.272204 ...
PET/CT performed with 18 F-FDG has become an established imaging modality in oncology (1,2). For several malignancies, including colorectal cancer, 18 F-FDG PET/CT examination is today recommended for ...
The necessity for standardization in clinical PET/CT protocols was acknowledged and initiated nearly 20 y ago (1–4). This recognition mainly stemmed from multicenter trials focused on quantifying and ...
The introduction of total-body PET, or long–axial-field-of-view (LAFOV) PET, has led to high-quality imaging by improving sensitivity through its increased axial coverage and volume of detector ...
PET/CT with 18F-FDG is an important noninvasive diagnostic tool for management of patients with lymphoma, and its use may surpass current guideline recommendations. The aim of the present study is to ...
There has been increasing focus on the side effects of radioactive iodine treatment (RAIT) given to patients with well-differentiated thyroid cancer (WDTC). The secondary malignancies evoke a ...
Bone metastases are common, especially in more prevalent malignancies such as breast and prostate cancer. They cause significant morbidity and draw on health-care resources. Molecular and hybrid ...
Introduction: Infections in Cardiovascular Implantable Electronic Device (CIED) are complications that pose extreme health risks to patients with implants such as pacemakers and defibrillators.
Purpose: Lu-177-DOTATATE (Lutathera®), a type of peptide receptor radionuclide therapy (PRRT) targeting the somatostatin receptor (SSTR), has been shown effective in patients with metastatic ...
Journal of Nuclear Medicine May 2024, jnumed.124.267417; DOI: https://doi.org/10.2967/jnumed.124.267417 ...
We developed a new C-X-C chemokine receptor 4 (CXCR4)–targeting radiolabeled peptide, [68Ga]Ga/[177Lu]Lu-BL34, using a novel and potent cyclic peptide based on structure–activity relationship studies ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results